SCHEMBL1979597

SCHEMBL1979597

CCc1ccccc1Oc1ccc(N2C(=O)NC(C)(C)C2=O)cn1

nearest known ligand 0.47

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
AR P10275 8/20 0.47
OXTR P30559 1/20 0.46
SLC6A2 P23975 2/20 0.40
SLC6A4 P31645 2/20 0.40
SLC6A3 Q01959 2/20 0.40
ALDH1A1 P00352 5/20 0.39
HTT P42858 2/20 0.38
TP53 P04637 1/20 0.38
TSHR P16473 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.36
MMP13 P45452 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30939562 1.00 AR (0.47) AROXTRSLC6A2SLC6A4SLC6A3
SCHEMBL1982711 0.83 AR (0.46) ARALDH1A1HTTTP53TSHR
SCHEMBL1984809 0.82 AR (0.43) ARSLC6A4SLC6A3ALDH1A1
SCHEMBL22026242 0.82 AR (0.47) ARSLC6A2SLC6A4SLC6A3ALDH1A1
SCHEMBL13828612 0.82 AR (0.52) AROXTRALDH1A1HTTTSHR
SCHEMBL12594118 0.79 AR (0.42) ARHTTTP53TSHRMMP13
SCHEMBL21116329 0.78 AR (0.39) ARALDH1A1HTTTP53TSHR
SCHEMBL30939511 0.78 OXTR (0.46) AROXTRSLC6A4TP53TSHR
SCHEMBL1980479 0.78 OXTR (0.46) AROXTRSLC6A4TP53TSHR
SCHEMBL30939608 0.78 AR (0.50) AROXTRHTTTP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10632118-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2020-04-28 US claimed
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-11-29 US claimed
US-10058551-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2018-08-28 US claimed
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-01-25 US claimed
US-9849131-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2017-12-26 US claimed
US-20170065585-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2017-03-09 US claimed
EP-2509961-B1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LTD (GB) 2016-03-09 EP claimed
US-20160058737-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2016-03-03 US claimed
US-8722695-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2014-05-13 US claimed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 US claimed
EP-2509961-A1 IMIDAZOLIDINEDIONE DERIVATIVES Autifony Therapeutics Limited (GB) 2012-10-17 EP claimed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 WO claimed
US-20250017925-A1 MODULATORS OF KV3 CHANNELS TO TREAT PAIN AUTIFONY THERAPEUTICS LIMITED (GB) 2025-01-16 US disclosed
CN-118267386-A Modulators of KV3 channels for the treatment of pain 奥提芙尼治疗学有限公司 2024-07-02 CN disclosed
CN-108472288-B Modulators of KV3 channels for the treatment of pain 奥提芙尼治疗学有限公司 2024-05-28 CN disclosed
US-11944623-B2 Modulators of Kv3 channels to treat pain AUTIFONY THERAPEUTICS LIMITED (GB) 2024-04-02 US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 US disclosed
EP-2509961-A1 IMIDAZOLIDINEDIONE DERIVATIVES Autifony Therapeutics Limited (GB) 2012-10-17 EP disclosed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 WO disclosed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 AR 4780/4885OXTR 890/4885SLC6A2 432/4885
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 AR 4780/4885OXTR 890/4885SLC6A2 432/4885
US-10632118-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 AR 4780/4885OXTR 890/4885SLC6A2 432/4885
US-20170065585-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 AR 4780/4885OXTR 890/4885SLC6A2 432/4885
US-20160058737-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 AR 4780/4885OXTR 890/4885SLC6A2 432/4885
US-10058551-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 AR 4780/4885OXTR 890/4885SLC6A2 432/4885
US-11944623-B2 Modulators of Kv3 channels to treat pain KCNN3, KCNA3, KCND3 AR 4434/4885OXTR 1116/4885SLC6A2 408/4885
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 AR 4638/4885OXTR 1143/4885SLC6A2 418/4885
US-20250017925-A1 MODULATORS OF KV3 CHANNELS TO TREAT PAIN KCNN3, KCNA3, KCND3 AR 4434/4885OXTR 1116/4885SLC6A2 408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.